Using current techniques, Alzheimer’s disease, the most frequent cause of dementia, can only be detected once the typical plaques have formed in the brain. At this point, therapy seems no longer possible. However, the first changes caused by Alzheimer’s take place on the protein level up to 20 years sooner. A two-tier method developed at Ruhr-Universität Bochum (RUB) can help detect the disease at a much earlier stage. The researchers from Bochum published their report in the March 2019 edition of the journal “Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring”.
“This has paved the way for early-stage therapy approaches, where the as yet inefficient drugs on which we had pinned our hopes may prove effective,” says Professor Klaus Gerwert from the Department of Biophysics at RUB.
Protein folds incorrectly
In Alzheimer’s patients, the amyloid beta protein folds incorrectly due to pathological changes long before the first symptoms occur. A team of researchers headed by Klaus Gerwert successfully diagnosed this misfolding using a simple blood test; as a result, the disease can be detected approximately eight years before the first clinical symptoms occur. The test wasn’t suitable for clinical applications however: it did detect 71 per cent of Alzheimer’s cases in symptomless stages, but at the same time provided false positive diagnoses for nine per cent of the study participants. In order to increase the number of correctly identified Alzheimer’s cases and to reduce the number of false positive diagnoses, the researchers poured a lot of time and effort into optimising the test.
As a result, they have now introduced the two-tier diagnostic method. To this end, they use the original blood test to identify high-risk individuals. Subsequently, they add a dementia-specific biomarker, namely tau protein, to run further tests with those test participants whose Alzheimer’s diagnosis was positive in the first step. If both biomarkers show a positive result, there is a high likelihood of Alzheimer’s disease. “Through the combination of both analyses, 87 of 100 Alzheimer’s patients were correctly identified in our study,” summarises Klaus Gerwert. “And we reduced the number of false positive diagnoses in healthy subjects to 3 of 100. The second analysis is carried out in cerebrospinal fluid that is extracted from the spinal cord.
“Now, new clinical studies with test participants in very early stages of the disease can be launched,” points out Gerwert. He is hoping that the existing therapeutic antibodies will still have an effect. “Recently, two major promising studies have failed, especially Crenezumab and Aducanumab – not least because it had probably already been too late by the time therapy was taken up. The new test opens up a new therapy window.”
“Once amyloid plaques have formed, it seems that the disease can no longer be treated,” says Dr. Andreas Nabers, head of the research group and co-developer of the Alzheimer’s sensor. “If our attempts to arrest the progression of Alzheimer’s fail, it will put a lot of strain on our society.”
Sensor test is simple and robust
The blood test has been upgraded to a fully automated process at the RUB Department of Biophysics. “The sensor is easy to use, robust when it comes to fluctuation in concentration of biomarkers, and standardised,” explains Andreas Nabers. “We are now conducting in-depth research to detect the second biomarker, namely tau protein, in the blood, in order to supply a solely blood-based test in future,” concludes Klaus Gerwert.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Gamechanger: Blood test can predict if patients will develop Alzheimer's disease in the futureon December 1, 2020 at 9:14 pm
Scientists said Monday they had developed a way of predicting if patients will develop Alzheimer's disease by analysing their blood, in what experts hailed as a potential "gamechanger" in the fight ...
- New tests identify early changes in Alzheimer’s disease before symptoms appearon December 1, 2020 at 8:11 pm
Researchers have found new forms of tau protein that become abnormal in the very early stages of Alzheimer's disease before cognitive problems develop. The scientists developed new tools to detect ...
- First Alzheimer's blood test now on the market, without FDA approvalon December 1, 2020 at 1:00 pm
More than 5 million people in the United States and millions more around the world have Alzheimer's, the most common form of dementia.
- New blood test to help diagnose Alzheimer's comes with a caveaton December 1, 2020 at 10:27 am
The new test is not approved by the FDA and is not supported by the Alzheimer's Association. But advocates are encouraged by the research.
- First Alzheimer’s Blood Test Now On Sale Only With Doctor’s Orderon December 1, 2020 at 10:21 am
AP reports that the blood test has not been approved by the FDA and is not covered by insurance or Medicare. Its maker, C2N Diagnostics of St. Louis, charges $1,250 and offers discounts based on ...
- AI uses retinal scans to spot Alzheimer’son December 1, 2020 at 10:01 am
A new AI model that examines retina images for changes that point to Alzheimer's disease may one day help diagnose the disease.
- Could Dirty Air Help Speed Alzheimer's?on December 1, 2020 at 8:47 am
Older adults exposed to air pollution might have a heightened risk of abnormal "plaque" accumulation in the brain, a new study suggests. Plaques refer to clumps of protein called beta-amyloid that ...
- First blood test to help diagnose Alzheimer’s goes on saleon December 1, 2020 at 8:37 am
AP A company has started selling the first blood test to help diagnose Alzheimer’s disease, a leap for the field that could make it much easier for people to learn whether they have dementia. It also ...
- Blood test for Alzheimer's goes on sale without FDA approvalon December 1, 2020 at 7:44 am
St. Louis-based C2N Diagnostics has released a blood test that it says can detect Alzheimer's disease. The test is not yet FDA approved, and is not covered by insurance, costing up to $1,250.
- Cleveland-Area Resident Elected to Lead Alzheimer's Association Board of Directorson December 1, 2020 at 7:00 am
The Alzheimer's Association has elected Brian J. Richardson from Avon Lake, Ohio, as Chair of its Board of Directors. Richardson, who was first elected to the Association's Board of Directors in 2013, ...
via Bing News